Research programme: glutamate modulators - Biohaven Pharmaceutical Holding Company

Drug Profile

Research programme: glutamate modulators - Biohaven Pharmaceutical Holding Company

Alternative Names: Glutamatergic agents - Biohaven; Neuropsychiatric disorder therapeutics - Biohaven; Riluzole - Biohaven

Latest Information Update: 26 Oct 2015

Price : $50

At a glance

  • Originator Fox Chase Chemical Diversity Center; Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; Glutamate-release-inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Mental disorders

Most Recent Events

  • 01 Oct 2015 Biohaven and Fox Chase Chemical Diversity Center agree to develop glutamate modulators
  • 18 Aug 2015 Biohaven acquires Glutamate modulator prodrugs from ALS Biopharma
  • 18 Aug 2015 Fox-Chase-Chemical Diversity center received SBIR grant from US-national Institute of Health for Glutamate modulator prodrugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top